RARA CRAFT DATABASE for FDA Medical Devices
510(k)K161251

FDA DEVICE FACTS

CLUNGENE Amphetamine Tests, CLUNGENE Cocaine Tests, CLUNGENE Oxazepam Tests

Hangzhou Clongene Biotech Co., Ltd.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEAugust 30, 2016PRODUCT CODEDKZ

Indications for use

CLUNGENE Amphetamine Tests are immunochromatographic assays for the qualitative determination of d- Amphetamine in human urine at cut-off concentration of 1000 ng/mL. The tests are available in a Cassette format, a Cup format, a Dip Card format, and a Split Key Cup format. The tests provide only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive. For in vitro diagnostic use only. The tests are intended for over-the-counter and for prescription use. CLUNGENE Cocaine Tests are immunochromatographic assays for the qualitative determination of Cocaine in human urine at cut-off concentration of 300 ng/mL. The tests are available in a Cassette format, a Cup format, a Dip Card format, and a Split Key Cup format. The tests provide only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive. For in vitro diagnostic use only. The tests are intended for over-the-counter and for prescription use. CLUNGENE Oxazepam Tests are immunochromatographic assays for the qualitative determination of Oxazepam in human urine at cut-off concentration of 300 ng/mL. The tests are available in a Cassette format, a Cup format, a Dip Card format, and a Split Key Cup format. The test may yield preliminary positive results even when prescription drug Oxazepam is ingested, at prescribed doses; it is not intended to distinguish between prescription use or abuse of this drug. There is no uniformly recognized cutoff concentration level for Oxazepam in urine. The tests provide only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive. For in vitro diagnostic use only. The tests are intended for over-the-counter and for prescription use.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: September 2, 2026